PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents growing 79.31% while AXSM's declined -16.64%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Below half of AXSM's -16.64%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
Below half of AXSM's -16.52%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.11%
0.5-0.75x AXSM's -8.30%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Higher Other Non-Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-0.83%
Below half of AXSM's -3.49%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Below half of AXSM's -16.46%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-6.24%
Less than half of AXSM's -27.13%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Less than half of AXSM's 66.06%. David Dodd sees fewer expansions in other current obligations.
-14.04%
Less than half of AXSM's 2.34%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Above 1.5x AXSM's -3.13%. Michael Burry sees a potential leverage warning sign.
36.75%
Above 1.5x AXSM's 0.25%. Michael Burry suspects heavy new equity expansion or dilution.
-4.17%
Below half AXSM's -10.26%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.37%
Less than half of AXSM's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
105.08%
Below half AXSM's -26.00%. Michael Burry sees potential underperformance in building shareholder capital.
67.39%
Below half AXSM's -16.46%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Less than half of AXSM's 22.98%. David Dodd sees better deleveraging or stronger cash buildup than competitor.